Sensitivity Analysis for 1-sample MR with Exclusion of Patients with a Diagnosis of Hyperthyroidism or Hypothyroidism
| Analysis . | Exposure . | OR Thyroid Cancer . | 95% CI . | OR Benign Nodular Thyroid Disease . | 95% CI . |
|---|---|---|---|---|---|
| Primary analysis | BMI | 1.18 | 0.55-2.52 | 0.87 | 0.61-1.25 |
| WHR | 1.45 | 0.55-3.85 | 1.52 | 0.93-2.50 | |
| adjWHR | 0.80 | 0.53-1.21 | 1.07 | 0.86-1.32 | |
| T2DM | 1.22 | 0.89-1.69 | 0.99 | 0.84-1.16 | |
| FA | 0.99 | 0.95-1.03 | 1.01 | 0.98-1.08 | |
| Sensitivity analysis | BMI | 1.18 | 0.55-2.52 | 0.86 | 0.60-1.22 |
| WHR | 1.45 | 0.55-3.85 | 1.55 | 0.94-2.54 | |
| adjWHR | 0.79 | 0.52-1.19 | 1.06 | 0.86-1.32 | |
| T2DM | 1.23 | 0.98-1.70 | 0.99 | 0.84-1.16 | |
| FA | 0.99 | 0.95-1.09 | 1.01 | 0.99-1.04 |
| Analysis . | Exposure . | OR Thyroid Cancer . | 95% CI . | OR Benign Nodular Thyroid Disease . | 95% CI . |
|---|---|---|---|---|---|
| Primary analysis | BMI | 1.18 | 0.55-2.52 | 0.87 | 0.61-1.25 |
| WHR | 1.45 | 0.55-3.85 | 1.52 | 0.93-2.50 | |
| adjWHR | 0.80 | 0.53-1.21 | 1.07 | 0.86-1.32 | |
| T2DM | 1.22 | 0.89-1.69 | 0.99 | 0.84-1.16 | |
| FA | 0.99 | 0.95-1.03 | 1.01 | 0.98-1.08 | |
| Sensitivity analysis | BMI | 1.18 | 0.55-2.52 | 0.86 | 0.60-1.22 |
| WHR | 1.45 | 0.55-3.85 | 1.55 | 0.94-2.54 | |
| adjWHR | 0.79 | 0.52-1.19 | 1.06 | 0.86-1.32 | |
| T2DM | 1.23 | 0.98-1.70 | 0.99 | 0.84-1.16 | |
| FA | 0.99 | 0.95-1.09 | 1.01 | 0.99-1.04 |
adjWHR, WHR adjusted for BMI; BMI, body mass index; CI, confidence interval; FA, favourable adiposity; OR, odds ratio; T2DM, type 2 diabetes mellitus; WHR, waist-hip ratio.
Sensitivity Analysis for 1-sample MR with Exclusion of Patients with a Diagnosis of Hyperthyroidism or Hypothyroidism
| Analysis . | Exposure . | OR Thyroid Cancer . | 95% CI . | OR Benign Nodular Thyroid Disease . | 95% CI . |
|---|---|---|---|---|---|
| Primary analysis | BMI | 1.18 | 0.55-2.52 | 0.87 | 0.61-1.25 |
| WHR | 1.45 | 0.55-3.85 | 1.52 | 0.93-2.50 | |
| adjWHR | 0.80 | 0.53-1.21 | 1.07 | 0.86-1.32 | |
| T2DM | 1.22 | 0.89-1.69 | 0.99 | 0.84-1.16 | |
| FA | 0.99 | 0.95-1.03 | 1.01 | 0.98-1.08 | |
| Sensitivity analysis | BMI | 1.18 | 0.55-2.52 | 0.86 | 0.60-1.22 |
| WHR | 1.45 | 0.55-3.85 | 1.55 | 0.94-2.54 | |
| adjWHR | 0.79 | 0.52-1.19 | 1.06 | 0.86-1.32 | |
| T2DM | 1.23 | 0.98-1.70 | 0.99 | 0.84-1.16 | |
| FA | 0.99 | 0.95-1.09 | 1.01 | 0.99-1.04 |
| Analysis . | Exposure . | OR Thyroid Cancer . | 95% CI . | OR Benign Nodular Thyroid Disease . | 95% CI . |
|---|---|---|---|---|---|
| Primary analysis | BMI | 1.18 | 0.55-2.52 | 0.87 | 0.61-1.25 |
| WHR | 1.45 | 0.55-3.85 | 1.52 | 0.93-2.50 | |
| adjWHR | 0.80 | 0.53-1.21 | 1.07 | 0.86-1.32 | |
| T2DM | 1.22 | 0.89-1.69 | 0.99 | 0.84-1.16 | |
| FA | 0.99 | 0.95-1.03 | 1.01 | 0.98-1.08 | |
| Sensitivity analysis | BMI | 1.18 | 0.55-2.52 | 0.86 | 0.60-1.22 |
| WHR | 1.45 | 0.55-3.85 | 1.55 | 0.94-2.54 | |
| adjWHR | 0.79 | 0.52-1.19 | 1.06 | 0.86-1.32 | |
| T2DM | 1.23 | 0.98-1.70 | 0.99 | 0.84-1.16 | |
| FA | 0.99 | 0.95-1.09 | 1.01 | 0.99-1.04 |
adjWHR, WHR adjusted for BMI; BMI, body mass index; CI, confidence interval; FA, favourable adiposity; OR, odds ratio; T2DM, type 2 diabetes mellitus; WHR, waist-hip ratio.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
